Notably, a humanized anti-STAB1 antibody has been evaluated in patients with various solid tumors, including immunotherapy-refractory melanoma (melanoma progression on or after anti-PD-1/CTLA-4 therapy), pancreatic-ductal adenocarcinoma, cholangiocarcinoma, hepatocellular carcinoma, ovarian carcinoma, and CRC [71]. This evidence concerns the gene CTLA4 and melanoma.